Carboplatin

Generic Name
Carboplatin
Brand Names
Paraplatin
Drug Type
Small Molecule
Chemical Formula
C6H12N2O4Pt
CAS Number
41575-94-4
Unique Ingredient Identifier
BG3F62OND5
Background

Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication

Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions
Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
Associated Therapies
Conditioning regimens for allogeneic stem cell transplantation therapy
Clinical Trials
Related News

A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma

First Posted Date
2023-09-28
Last Posted Date
2024-10-28
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
64
Registration Number
NCT06057935
Locations
🇺🇸

University of Chicago (Data Collection Only), Chicago, Illinois, United States

🇺🇸

University of Michigan (Data Collection Only), Ann Arbor, Michigan, United States

🇺🇸

University of Nebraska (Data collection only), Omaha, Nebraska, United States

and more 10 locations

A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors

First Posted Date
2023-09-28
Last Posted Date
2024-12-20
Lead Sponsor
Genmab
Target Recruit Count
42
Registration Number
NCT06057038
Locations
🇯🇵

National Cancer Center East, Kashiwa, Japan

🇯🇵

National Cancer Center Hospital, Tokyo, Japan

Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC

First Posted Date
2023-09-25
Last Posted Date
2024-02-07
Lead Sponsor
Dan Zandberg
Target Recruit Count
15
Registration Number
NCT06052839
Locations
🇺🇸

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

Atezolizumab in Large Cell Neuroendocrine Carcinoma

First Posted Date
2023-09-22
Last Posted Date
2023-09-22
Lead Sponsor
Oncology Center of Biochemical Education And Research
Target Recruit Count
22
Registration Number
NCT06049966
Locations
🇬🇷

OCEBER, Athens, Greece

🇬🇷

National and Kapodistrian University of Athens, Athens, Greece

Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)

First Posted Date
2023-09-22
Last Posted Date
2024-12-02
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
36
Registration Number
NCT06049212
Locations
🇯🇵

National Hospital Organization Shikoku Cancer Center ( Site 0008), Matsuyama, Ehime, Japan

🇯🇵

Aichi Cancer Center Hospital ( Site 0006), Nagoya, Aichi, Japan

🇯🇵

National Cancer Center Hospital East ( Site 0002), Kashiwa, Chiba, Japan

and more 4 locations

Safety and Efficacy of NEO212 in Patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

First Posted Date
2023-09-21
Last Posted Date
2024-10-16
Lead Sponsor
Neonc Technologies, Inc.
Target Recruit Count
134
Registration Number
NCT06047379
Locations
🇺🇸

Precision NextGen Oncology, Beverly Hills, California, United States

🇺🇸

Northwest Medical Specialties, Tacoma, Washington, United States

Supraphysiological Androgen to Enhance Chemotherapy Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study

First Posted Date
2023-09-15
Last Posted Date
2024-09-30
Lead Sponsor
University of Washington
Target Recruit Count
46
Registration Number
NCT06039371
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

First Posted Date
2023-09-08
Last Posted Date
2024-11-26
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
156
Registration Number
NCT06029270
Locations
🇺🇸

Oncology Associates PC, Omaha, Nebraska, United States

🇺🇸

Kaiser Permanente Dublin, Dublin, California, United States

🇺🇸

Kaiser Permanente-Fremont, Fremont, California, United States

and more 61 locations

IN10018 Combination Therapy in Treatment-naïve ES-SCLC

First Posted Date
2023-09-08
Last Posted Date
2023-11-21
Lead Sponsor
InxMed (Shanghai) Co., Ltd.
Target Recruit Count
120
Registration Number
NCT06030258
Locations
🇨🇳

Shandong Province Cancer Hospital, Jinan, China

🇨🇳

Tianjin Medical University Cancer Institute & Hospital, Tianjin, China

🇨🇳

Henan Provincial People's Hospital, Zhengzhou, China

Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer

First Posted Date
2023-09-07
Last Posted Date
2024-07-18
Lead Sponsor
Wake Forest University Health Sciences
Target Recruit Count
36
Registration Number
NCT06027268
Locations
🇺🇸

Levine Cancer Institute, Charlotte, North Carolina, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy